Bland and Altman representations of these differences are shown in Fig. 2, showing a proportional error, i.e., the difference between both methodologies is higher when E′ values are higher.
The degree of overlap between these methodologies was low suggesting they are complementary not redundant approaches to identify putative drug-gene interactions.
The relative error of the stress components σrr and σθθ between the methodologies was less than 3.8% within the range from the contact edge to 1 mm, and it increased gradually as the distance from the contact edge increased.
Results for both IHC and FISH were available from 3,280 patients, and concordance between the two methodologies was calculated with defined categories of IHC-positive (IHC 3+), IHC-negative (IHC 0, IHC 1+, and IHC 2+), FISH-positive, and FISH-negative.
The correlation coefficient (R) between methodologies was 0.85 for Amplicor; 0.87 for Versant; and 0.91 for Nuclisens.
The overall (positive and negative) concordance rate between methodologies was about 96%% in our cohort, which is in accordance with the American Society of Clinical Oncology/College of American Pathologists guideline that any two diagnostic companion tests should establish a concordance rate of >95%% for positive and negative assay values [ 14].
In this study, a comparative analysis between 2 rRNA depletion methodologies was performed, and the transcripts were submitted to ab initio assembly.
The difference between the two mRNA quantification methodologies was significant (p < 0.05) and consistent for both samples, as well as for their average, and did not depend on the sequence coverage depth, detection cutoff, or type of the correlation test used.
Our combined chromosome banding and CGH analysis of the remaining cell lines allowed a detailed genomic characterization of their chromosomal changes, and a very high concordance between the two genome screening methodologies was achieved.
